These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 9745414)
21. Serum levels of carboxyterminal propeptide of type I procollagen and pyridinoline crosslinked telopeptide of type I collagen in normal children and children with growth hormone (GH) deficiency during GH therapy. Kubo T; Tanaka H; Inoue M; Kanzaki S; Seino Y Bone; 1995 Oct; 17(4):397-401. PubMed ID: 8573414 [TBL] [Abstract][Full Text] [Related]
22. Effects of a growth hormone receptor antagonist on bone markers in acromegaly. Fairfield WP; Sesmilo G; Katznelson L; Pulaski K; Freda PU; Stavrou S; Kleinberg D; Klibanski A Clin Endocrinol (Oxf); 2002 Sep; 57(3):385-90. PubMed ID: 12201832 [TBL] [Abstract][Full Text] [Related]
23. Modifications of growth velocity and the insulin-like growth factor system in children with acute lymphoblastic leukemia: a longitudinal study. Argüelles B; Barrios V; Pozo J; Muñoz MT; Argente J J Clin Endocrinol Metab; 2000 Nov; 85(11):4087-92. PubMed ID: 11095437 [TBL] [Abstract][Full Text] [Related]
24. The growth hormone/insulin-like growth factor-I axis hormones and bone markers in elite athletes in response to a maximum exercise test. Ehrnborg C; Lange KH; Dall R; Christiansen JS; Lundberg PA; Baxter RC; Boroujerdi MA; Bengtsson BA; Healey ML; Pentecost C; Longobardi S; Napoli R; Rosén T; J Clin Endocrinol Metab; 2003 Jan; 88(1):394-401. PubMed ID: 12519882 [TBL] [Abstract][Full Text] [Related]
25. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women. Garnero P; Tsouderos Y; Marton I; Pelissier C; Varin C; Delmas PD J Clin Endocrinol Metab; 1999 Jul; 84(7):2390-7. PubMed ID: 10404809 [TBL] [Abstract][Full Text] [Related]
26. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer. Akimoto S; Akakura K; Shimazaki J Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556 [TBL] [Abstract][Full Text] [Related]
27. Growth hormone (GH) treatment of GH-deficient children increases serum levels of insulin-like growth factors (IGFs), IGF-binding protein-3 and -5, and bone alkaline phosphatase isoenzyme. Ono T; Kanzaki S; Seino Y; Baylink DJ; Mohan S J Clin Endocrinol Metab; 1996 Jun; 81(6):2111-6. PubMed ID: 8964836 [TBL] [Abstract][Full Text] [Related]
28. Relationships of serum leptin levels with biochemical markers of bone turnover and with growth factors in normal weight and overweight children. Bini V; Igli Baroncelli G; Papi F; Celi F; Saggese G; Falorni A Horm Res; 2004; 61(4):170-5. PubMed ID: 14726619 [TBL] [Abstract][Full Text] [Related]
29. [Studies of type I collagen related substances as bone metastatic markers of prostate carcinoma with special regard to serum carboxyterminal propeptide of type. I. Procollagen (PICP), cross-linked carboxyterminal telopeptide of type I collagen (ICTP) and Urinary deoxypyridinoline levels]. Imai T; Honda M; Maeda S; Hosoya Y; Arai T; Sumi S; Umeda H; Yano M; Koga F; Arai K; Yoshida K Nihon Hinyokika Gakkai Zasshi; 1998 Apr; 89(4):484-91. PubMed ID: 9597867 [TBL] [Abstract][Full Text] [Related]
30. Influence of demographic factors and sport type on growth hormone-responsive markers in elite athletes. Nelson AE; Howe CJ; Nguyen TV; Leung KC; Trout GJ; Seibel MJ; Baxter RC; Handelsman DJ; Kazlauskas R; Ho KK J Clin Endocrinol Metab; 2006 Nov; 91(11):4424-32. PubMed ID: 16912136 [TBL] [Abstract][Full Text] [Related]
32. Urinary pyridinium collagen cross-links predict growth performance in children with idiopathic short stature and with growth hormone (GH) deficiency treated with GH. Skeletal metabolism during GH treatment. Spagnoli A; Branca F; Spadoni GL; Cianfarani S; Pasquino AM; Argirò G; Vitale S; Robins SP; Boscherini B J Clin Endocrinol Metab; 1996 Oct; 81(10):3589-93. PubMed ID: 8855806 [TBL] [Abstract][Full Text] [Related]
33. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults. Välimäki MJ; Salmela PI; Salmi J; Viikari J; Kataja M; Turunen H; Soppi E Eur J Endocrinol; 1999 Jun; 140(6):545-54. PubMed ID: 10377504 [TBL] [Abstract][Full Text] [Related]
34. Elite volunteer athletes of different sport disciplines may have elevated baseline GH levels divorced from unaltered levels of both IGF-I and GH-dependent bone and collagen markers: a study on-the-field. Sartorio A; Marazzi N; Agosti F; Faglia G; Corradini C; De Palo E; Cella S; Rigamonti A; Muller EE J Endocrinol Invest; 2004 May; 27(5):410-5. PubMed ID: 15279071 [TBL] [Abstract][Full Text] [Related]
35. Short-term growth and collagen turnover in asthmatic adolescents treated with the inhaled glucocorticoid budesonide. Heuck C; Wolthers OD; Hansen M; Kollerup G Steroids; 1997 Oct; 62(10):659-64. PubMed ID: 9381513 [TBL] [Abstract][Full Text] [Related]
36. [Effect of GH/IGF-I deficiency on bone and collagen turnover in children and adults with GH deficiency]. Sartorio A; Conti A; Monzani M; Ferrero S; Biella O; Casati G; Faglia G Minerva Endocrinol; 1995 Jun; 20(2):135-40. PubMed ID: 8531895 [TBL] [Abstract][Full Text] [Related]
37. Effect of growth hormone (GH) replacement on plasma carboxy-terminal propeptide of type I procollagen (PICP) and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) levels in GH-deficient adult patients. Murakami Y; Sugitani M; Koshimura K; Sohmiya M; Kato Y Endocr J; 1998 Apr; 45 Suppl():S121-4. PubMed ID: 9790245 [No Abstract] [Full Text] [Related]
38. Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major. Sartorio A; Conte G; Conti A; Masala A; Alagna S; Rovasio P; Faglia G J Endocrinol Invest; 2000 Jun; 23(6):356-61. PubMed ID: 10908162 [TBL] [Abstract][Full Text] [Related]
39. Bone Turnover and Growth during and after Chemotherapy in Children with Solid Tumors. Bath LF; Crofton PM; Evans AE; Ranke MB; Elmlinger MW; Kelnar CJ; Wallace WH Pediatr Res; 2004 Feb; 55(2):224-30. PubMed ID: 14605245 [TBL] [Abstract][Full Text] [Related]
40. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males. Svensson J; Ohlsson C; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Baylink D; Mohan S; Bengtsson BA J Bone Miner Res; 1998 Jul; 13(7):1158-66. PubMed ID: 9661080 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]